Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study investigated various compounds inhibiting testosterone 5alpha-reductase for potential treatment of benign prostatic hyperplasia, finding that heparin and progesterone demonstrated inhibitory effects under specific conditions.

This review discusses the impact of COVID-19 on lower urinary tract symptoms and benign prostatic enlargement, noting altered patient care and management, but provides no new clinical results.

This review discusses the rationale for targeting 5α-reductase isoenzymes in prostate cancer prevention and treatment, highlighting the potential benefits of using inhibitors like dutasteride and finasteride but reports no new experimental results.

This study found that finasteride significantly reduced VEGF expression and microvessel density in prostatic suburethral tissue, suggesting a mechanism for decreased bleeding in patients with benign prostatic hyperplasia.

This review discusses the use of 5α-reductase inhibitors in treating benign prostatic hyperplasia, highlighting their long-term effectiveness and benefits when combined with α1-adrenergic antagonists; it reports no new clinical results.

In this study, short-term finasteride treatment reduced apoptotic factors caspase-7 and IGFBP-3 in prostate cancer cells but did not significantly affect androgen receptor expression compared to placebo.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

In this study, 4‐MAPC treatment reduced ventral prostate weight in rats primarily through decreased synthetic activity, with testosterone propionate increasing prostate weight and activity at pharmacologic doses.

This article discusses the potential of using flutamide and finasteride for complete androgen blockade in early-stage, low-grade prostate cancer and suggests they may improve symptom-free and overall survival compared to observation.

This study found that certain Y-chromosome alleles may influence susceptibility to prostate cancer among Iraqi males, suggesting potential genetic screening markers for the disease.

This study found that in patients undergoing allogeneic hematopoietic stem-cell transplantation, older age significantly increases the risk of hemorrhagic cystitis, especially in males, who are also affected by prostatic hyperplasia.

This study found that metabolic syndrome significantly affects the response to benign prostatic hyperplasia medications, impacting clinical outcomes such as symptom scores, prostate volume, and quality of life among male patients.

This study observed that low-dose intrauterine exposure to finasteride alters postnatal prostate development in male and female Mongolian gerbils, showing sex-specific differences in receptor expression and tissue changes.

This study investigated the cytotoxic effects of DHA derivatives on cancer cell lines and found that didocosahexaenoin was the most potent, inducing apoptosis and producing reactive oxygen species in PC3 prostate carcinoma cells.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

This study found that vitamin D regulates cholesterol metabolism and may influence prostate cancer development through mechanisms affecting prostate cell growth and sex hormone metabolism.

This study observed that a 24-hour pre-treatment with MitoQ significantly protected H9c2 myoblasts from doxorubicin-induced damage while enhancing doxorubicin's effectiveness in prostate cancer cells, outperforming dexrazoxane's effects without compromising the anti-cancer efficacy.

This study found that combination therapy with alpha-adrenergic blockers and 5α-reductase inhibitors significantly improved urinary symptoms, reduced prostate volume, and decreased the risk of acute urinary retention and postoperative surgery in patients with benign prostatic hyperplasia compared to monotherapy.

This study found that BAMO acupuncture combined with Simiao pill can help restore normal prostate tissue structure in mice by reducing DHT production, promoting apoptosis, and decreasing inflammatory responses.

This abstract provides a directed acyclic graph of the association between chest hair amount and prostate cancer, highlighting variables and potential confounders, but it reports no new research findings.

This review discusses the potential of phytochemicals from plants as alternative treatments for prostate cancer, highlighting their possible benefits over current 5-alpha-Reductase inhibitors, but reports no new findings.

This study found that specific Y-chromosome alleles may influence susceptibility to prostate cancer in Iraqi males, suggesting their potential use in screening for the disease.

This study found that in rats, combined treatment with finasteride and doxazosin altered epithelial cell behavior and matrix metalloproteinases activity, suggesting effects possibly mediated by TGF-β1 and androgen pathways.

This review examines the use of 5-alpha-reductase inhibitors for treating benign prostatic hyperplasia, noting moderate positive effects without complete cure and the need for further research to understand drug mechanisms and pathogenesis.

In this study, Saw Palmetto at a physiological dose partially inhibited 5-α-reductase and improved hormonal balance, inflammation, and mitochondrial function, with synergy observed when combined with Lycopene, L-Arginine, and Astaxanthin, enhancing male prostatic and endocrine health without endocrine side effects.

This study reported that Saw Palmetto, at a physiological dose, partially inhibits 5-alpha-reductase and, when combined with Lycopene, L-Arginine, and Astaxanthin, demonstrates a synergistic effect in restoring hormonal balance, reducing inflammation, and improving hair density, urinary flow, and oxidative biomarkers in related male health conditions.

This study found that combination therapy with doxazosin and finasteride was more effective in preventing the clinical progression of benign prostatic hyperplasia than either drug alone.

This article discusses the potential link between genetic variants associated with androgen receptor activity and racial variations in COVID-19 mortality, suggesting a possible role for anti-androgens in treatment, but reports no new clinical findings.